Treatment strategy and therapy based on immune response in patients with gastric cancers

doi:10.4240/wjgs.v16.i8.2393

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (639)

All Articles published online

The chart showing PDF series, WORD series, HTML series.

Item

Count

PDF

WORD

HTML

367

Sum=379

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=173

Publishing Process of This Article

Item

Count

Browse

Download

Sum=73

Aug 27, 2024 (publication date) through Sep 17, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastrointest Surg. Aug 27, 2024; 16(8): 2393-2395
Published online Aug 27, 2024. doi: 10.4240/wjgs.v16.i8.2393

Treatment strategy and therapy based on immune response in patients with gastric cancers

Damian Jacenik, Jakub Fichna

Damian Jacenik, Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Lodz 90-236, Poland

Jakub Fichna, Department of Biochemistry, Medical University of Lodz, Lodz 92-215, Poland

Author contributions: Jacenik D and Fichna J wrote, reviewed and edited the manuscript; Jacenik D wrote the original draft and conceptualised the manuscript.

Conflict-of-interest statement: The authors declare having no conflicts of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Damian Jacenik, PhD, Assistant Professor, Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska St., Lodz 90-236, Poland. damian.jacenik@biol.uni.lodz.pl

Received: April 3, 2024
Revised: May 7, 2024
Accepted: June 4, 2024
Published online: August 27, 2024
Processing time: 135 Days and 8.9 Hours

Core Tip

Core Tip: Gastric cancer (GC) is a highly heterogenous disease that affects patients’ outcomes. Immunotherapy in GC patients seems to provide several clinical benefits, and retrospective studies are needed to evaluate immunotherapy efficiency and safety. The aim of this editorial is to provide a short and informative introduction elaborating the efficiency and safety of immunotherapy in patients with advanced GCs manifested by absence or presence of liver metastasis.